Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][3] - The company has an upcoming schedule of investor conferences in March 2026, where key executives will participate [2] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291 in Phase 1 development and multiple discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] - The company is based in Carmel, Indiana [3]
MBX Biosciences to Participate in Upcoming March Investor Conferences